IC
ELEV

Ikarian Capital’s Elevation Oncology ELEV Stock Holding History

Ikarian Capital’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-690,050
Closed -$179K – 155
2025
Q1 		$179K Hold
690,050
– – 0.02% 141
2024
Q4 		$388K Sell
690,050
-39
-0% -$23 0.05% 135
2024
Q3 		$414K Hold
690,089
– – 0.06% 120
2024
Q2 		$1.86M Buy
690,089
+542,000
+366% +$2.04M 0.32% 57
2024
Q1 		$760K Sell
148,089
-1,023,850
-87% -$3.32M 0.08% 112
2023
Q4 		$629K Hold
1,171,939
– – 0.06% 112
2023
Q3 		$777K Buy
1,171,939
+22,449
+2% +$22.7K 0.09% 103
2023
Q2 		$1.75M Buy
+1,149,490
New +$3.03M 0.28% 70

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Ikarian Capital's ELEV Position: Q2 2025 in Review

Ikarian Capital sold out of Elevation Oncology (ELEV) in Q2 2025, closing a stake of 690,050 shares — an estimated $179K sold.

Ikarian Capital first reported a position in ELEV in Q2 2023 and held it in 8 quarters. The position peaked at $1.86M in Q2 2024. 65 funds tracked by Wall St. Rank hold ELEV as of Q2 2025.

  • Ikarian Capital reported no remaining Elevation Oncology position as of Q2 2025 after selling out during the quarter.
  • Ikarian Capital sold 690,050 Elevation Oncology shares in Q2 2025, an estimated $179K.
  • Ikarian Capital first reported a position in Elevation Oncology in Q2 2023 and held it in 8 quarters.
  • Ikarian Capital's Elevation Oncology position peaked at $1.86M in Q2 2024.
  • 65 funds tracked by Wall St. Rank held Elevation Oncology as of Q2 2025.

Based on Ikarian Capital's 13F filing for Q2 2025, filed 14 Aug 2025.